XML 42 R29.htm IDEA: XBRL DOCUMENT v3.19.1
Concentration of credit risk (Tables)
 3 Months Ended
Mar. 31, 2019
Concentration of credit risk  
Schedule of concentration of credit risk related to collaborative partners

In December 2018, we entered into a research collaboration and licensing agreement with Innovent Biologics, Inc. (“Innovent”). The concentration of credit risk related to our collaborative partners is as follows:

 

 

 

 

 

 

 

 

 

Percentage of Total

 

 

 

Milestone and Contract Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2019

    

2018

    

 

Collaboration Partner A

    

 —

%  

 —

%  

 

Collaboration Partner B

 

 —

%  

 —

%  

 

Collaboration Partner C

 

100

%  

 —

%  

 

 

Schedule of concentration of credit risk related to specialty pharmacy customers

The concentration of credit risk related to our JAKAFI product revenues is as follows:

 

 

 

 

 

 

 

 

 

Percentage of Total Net

 

 

 

Product Revenues for the

 

 

 

Three Months Ended

 

 

 

March 31,

 

 

    

2019

    

2018

    

 

Customer A

    

18

%  

22

%  

 

Customer B

 

15

%  

13

%  

 

Customer C

 

16

%  

14

%  

 

Customer D

 

12

%  

11

%